Coronavirus Live Count Map India
remove_red_eye 562 Views
COVID-19 Vaccine Updates
#Gastroenterology #Pathology and Lab Medicine #Pharmacist #Public Health
Nearly 60% of patients with biopsy-confirmed nonalcoholic steatohepatitis and liver fibrosis reported NASH resolution following treatment with semaglutide, suggested a phase 2, double-blind, randomized, placebo-controlled trial.
Around 40% of patients treated with 0.1mg semaglutide, 36% given 0.2mg, and 59% receiving 0.4mg semaglutide achieved NASH resolution with no worsening of fibrosis, compared to 17% of those receiving placebo (odds ratio, 6.87;P< .001 for the highest semaglutide dose). There were no significant between-group differences in the secondary endpoint (improvement of fibrosis by at least one stage without worsening of NASH), which was evident in 43% of patients on the highest semaglutide dose compared to 33% in the placebo group (OR, 1.42; P= .48). The findings are published in the New England Journal of Medicine and were presented at the 2020 American Association for the Study of Liver Diseases (AASLD) meeting… (Medscape)